Literature DB >> 21794528

[Is the DAS28 Score the Most Adequate Method to Estimate Activity in Rheumatoid Arthritis? Clinimetric Considerations and Simulations Scenarios].

Miguel Ángel Belmonte Serrano1.   

Abstract

INTRODUCTION: The DAS28 score has now consolidated as a fundamental variable for the assessment of rheumatoid arthritis activity and is the main parameter used to establish therapeutic decisions in this disease, including the start and change of biologic therapies.
OBJECTIVES: We have studied the clinimetric properties of DAS28, including ceiling and floor effects and its behavior in several clinical scenarios. MATERIAL AND
METHOD: Individualized study of the variables included in the DAS28 formula along its possible range. Sensitivity analysis of the results of the DAS28 of 4 variables in four theoretical scenarios corresponding to low (DAS28=2.43), fair (DAS28=4.05), high (DAS28=6.32) or very high (DAS28=8.40) clinical activity.
RESULTS: Tender joint count (NAD) and erithrosedimentation rate (ESR) have a weight of 35- 40% each on the total DAS28 score, while swollen join count (SJC) and global health assessed by the patient (GH) only contribute with 15% each. As tender joints weights double than swollen joints, in the simulation models having one swollen joint needed just 3 tender joints to get the DAS28 above the non remission level (DAS28>2.6), while having one tender joint needed 5 swollen joints to be above remission. Given its logarithmic calculation in the DAS28 formula, ESR contribution is much higher in its lower range, and thus small variations of ESR in the normal range can influence decisively in the final DAS28 score.
CONCLUSIONS: The asymmetric weight of each component in the complex DAS28 formula must be taken into account when interpreting changes in the DAS28 lower range as they influence the estimation of clinical remission and thus can be relevant when taking therapeutic decisions.
Copyright © 2008 Elsevier España S.L Barcelona. Published by Elsevier Espana. All rights reserved.

Entities:  

Year:  2008        PMID: 21794528     DOI: 10.1016/S1699-258X(08)72462-8

Source DB:  PubMed          Journal:  Reumatol Clin        ISSN: 1699-258X


  12 in total

1.  Gender-associated comorbidities in rheumatoid arthritis and their impact on outcome: data from GENIRA.

Authors:  E Aurrecoechea; J Llorca Díaz; M L Diez Lizuain; G McGwin; J Calvo-Alen
Journal:  Rheumatol Int       Date:  2016-12-16       Impact factor: 2.631

2.  Correlation between rapid-3, DAS28, CDAI and SDAI as a measure of disease activity in a cohort of Colombian patients with rheumatoid arthritis.

Authors:  Jesus Giovanny Ballesteros Muñoz; Rodrigo B Giraldo; Ana M Santos; Juan Manuel Bello-Gualteros; Juan C Rueda; Eugenia-Lucia Saldarriaga; Jose-Ignacio Angarita; Sofia Arias-Correal; Andres Y Vasquez; John Londono
Journal:  Clin Rheumatol       Date:  2016-12-24       Impact factor: 2.980

3.  The effect of concomitant hand osteoarthritis on pain and disease activity in patients with rheumatoid arthritis.

Authors:  Emmanuel Ruiz-Medrano; Hector Fabricio Espinosa-Ortega; Cesar Alejandro Arce-Salinas
Journal:  Clin Rheumatol       Date:  2019-05-10       Impact factor: 2.980

4.  Exposure-response modeling of tocilizumab in rheumatoid arthritis using continuous composite measures and their individual components.

Authors:  Carla Bastida; Dolors Soy; Virginia Ruiz-Esquide; Raimon Sanmartí; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2019-06-17       Impact factor: 4.335

Review 5.  Methods of assessment of joint involvement in various systemic connective tissue diseases.

Authors:  Tobiasz Kardas; Ewa Wielosz; Maria Majdan
Journal:  Reumatologia       Date:  2022-02-28

6.  Contribution of ethnic group and socioeconomic status to degree of disability in rheumatoid arthritis in Chilean patients.

Authors:  Ana M Alarcón; Sergio Muñoz; Jay S Kaufman; Carlos Martínez; Pablo Riedemann; Sonia Kaliski
Journal:  Rheumatol Int       Date:  2014-09-02       Impact factor: 2.631

7.  Expression of MIF and TNFA in psoriatic arthritis: relationship with Th1/Th2/Th17 cytokine profiles and clinical variables.

Authors:  L A Bautista-Herrera; U De la Cruz-Mosso; R Morales-Zambrano; G D Villanueva-Quintero; J Hernández-Bello; M G Ramírez-Dueñas; E Martínez-López; L M Brennan-Bourdon; C J Baños-Hernández; J F Muñoz-Valle
Journal:  Clin Exp Med       Date:  2017-09-30       Impact factor: 3.984

8.  Long-term sustained remission in a cohort study of patients with rheumatoid arthritis: choice of remission criteria.

Authors:  Björn Svensson; Maria L E Andersson; Sidona-Valentina Bala; Kristina Forslind; Ingiäld Hafström
Journal:  BMJ Open       Date:  2013-09-10       Impact factor: 2.692

9.  Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis.

Authors:  Enrique R Soriano; Analia Dellepiane; Gabriela Salvatierra; Cristian Alejandro Benítez; Rodrigo Garcia Salinas; Carlos Baruzzo
Journal:  Future Sci OA       Date:  2018-02-15

10.  Measurement of Disease Activity in Ecuadorian Patients with Rheumatoid Arthritis: Does RAPID3 Correlate with Traditional Indexes?

Authors:  María Fernanda Zurita; Adriana Iglesias; Emanuel Vanegas; Adriana Luzuriaga; Luis Zurita
Journal:  ScientificWorldJournal       Date:  2019-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.